HK1159136A1 - High affinity human antibodies to human il-4 receptor - Google Patents

High affinity human antibodies to human il-4 receptor

Info

Publication number
HK1159136A1
HK1159136A1 HK11113779.7A HK11113779A HK1159136A1 HK 1159136 A1 HK1159136 A1 HK 1159136A1 HK 11113779 A HK11113779 A HK 11113779A HK 1159136 A1 HK1159136 A1 HK 1159136A1
Authority
HK
Hong Kong
Prior art keywords
human
receptor
high affinity
antibodies
human antibodies
Prior art date
Application number
HK11113779.7A
Other languages
English (en)
Inventor
Joel H Martin
Tammy T Huang
Jeanette L Fairhurst
Nicholas J Papadopoulos
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41600767&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1159136(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of HK1159136A1 publication Critical patent/HK1159136A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Reproductive Health (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
HK11113779.7A 2008-10-29 2011-12-21 High affinity human antibodies to human il-4 receptor HK1159136A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12/260,307 US7608693B2 (en) 2006-10-02 2008-10-29 High affinity human antibodies to human IL-4 receptor
PCT/US2009/062168 WO2010053751A1 (en) 2008-10-29 2009-10-27 High affinity human antibodies to human il-4 receptor

Publications (1)

Publication Number Publication Date
HK1159136A1 true HK1159136A1 (en) 2012-07-27

Family

ID=41600767

Family Applications (2)

Application Number Title Priority Date Filing Date
HK11113779.7A HK1159136A1 (en) 2008-10-29 2011-12-21 High affinity human antibodies to human il-4 receptor
HK18110192.5A HK1250733A1 (zh) 2008-10-29 2018-08-08 抗人il-4受體的高親和性人抗體的製藥用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK18110192.5A HK1250733A1 (zh) 2008-10-29 2018-08-08 抗人il-4受體的高親和性人抗體的製藥用途

Country Status (48)

Country Link
US (7) US7608693B2 (el)
EP (7) EP3715372B1 (el)
JP (8) JP5291802B2 (el)
KR (1) KR101599706B1 (el)
CN (3) CN106267190B (el)
AR (1) AR073978A1 (el)
AU (1) AU2009311496B9 (el)
BR (1) BRPI0919853B8 (el)
CA (1) CA2737044C (el)
CL (1) CL2009002004A1 (el)
CO (1) CO6362024A2 (el)
CR (1) CR20110148A (el)
CY (3) CY1114123T1 (el)
DK (3) DK3715372T5 (el)
EC (1) ECSP11011010A (el)
ES (4) ES2802241T3 (el)
FI (1) FI3715372T3 (el)
FR (1) FR18C1011I2 (el)
HK (2) HK1159136A1 (el)
HN (1) HN2011001210A (el)
HR (3) HRP20240492T1 (el)
HU (2) HUS1800014I1 (el)
IL (1) IL211726A (el)
JO (1) JO2865B1 (el)
LT (3) LT3715372T (el)
LU (1) LUC00059I2 (el)
MA (1) MA32802B1 (el)
MX (2) MX356882B (el)
MY (1) MY152448A (el)
NI (1) NI201100064A (el)
NL (1) NL300922I2 (el)
NO (2) NO2018009I2 (el)
NZ (2) NZ596093A (el)
PA (1) PA8847001A1 (el)
PE (1) PE20100738A1 (el)
PH (1) PH12014500462A1 (el)
PL (4) PL3715372T3 (el)
PT (4) PT3351560T (el)
RS (3) RS65385B1 (el)
RU (2) RU2539774C3 (el)
SI (3) SI3064511T1 (el)
SM (1) SMT201300074B (el)
SV (1) SV2011003880A (el)
TW (3) TW201919700A (el)
UA (1) UA102122C2 (el)
UY (1) UY32213A (el)
WO (1) WO2010053751A1 (el)
ZA (1) ZA201101867B (el)

Families Citing this family (132)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7763249B2 (en) * 2004-04-27 2010-07-27 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Human anti-amyloid β peptide antibody and fragment of said antibody
DK2069403T3 (da) * 2006-10-02 2014-07-28 Regeneron Pharma Human-antistoffer med høj affinitet for human IL-4 receptor
US7608693B2 (en) * 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
US20130064834A1 (en) 2008-12-15 2013-03-14 Regeneron Pharmaceuticals, Inc. Methods for treating hypercholesterolemia using antibodies to pcsk9
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
EP2501817B2 (en) 2010-02-08 2021-04-21 Regeneron Pharmaceuticals, Inc. Common light chain mouse
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
US20120021409A1 (en) * 2010-02-08 2012-01-26 Regeneron Pharmaceuticals, Inc. Common Light Chain Mouse
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
EP3354280B1 (en) * 2010-10-06 2020-07-29 Regeneron Pharmaceuticals, Inc. Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies
UA111731C2 (uk) * 2010-10-06 2016-06-10 Рідженерон Фармасьютікалз, Інк. Стабілізована композиція, яка містить антитіло до рецептора інтерлейкіну-4 (іl-4r), варіанти
MX347602B (es) 2011-01-28 2017-05-03 Sanofi Biotechnology Composiciones farmaceuticas que comprenden anticuerpos humanos frente a pcsk9.
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
JP6510234B2 (ja) 2011-08-05 2019-05-08 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． ヒト化ユニバーサル軽鎖マウス
KR101964031B1 (ko) 2011-09-16 2019-04-02 리제너론 파아마슈티컬스, 인크. 전구단백질 전환효소 서브틸리신 켁신-9 (ＰＣＳＫ9)의 억제제를 투여함으로써 지질단백질(ａ)의 농도를 낮추는 방법
EA029290B1 (ru) * 2011-12-22 2018-03-30 Астеллас Фарма Инк. Новое антитело против ctgf человека
RU2018128915A (ru) 2012-03-16 2019-02-18 Регенерон Фармасьютикалз, Инк. ОТЛИЧНЫЕ ОТ ЧЕЛОВЕКА ЖИВОТНЫЕ, ЭКСПРЕССИРУЮЩИЕ ЧУВСТВИТЕЛЬНЫЕ К рН ПОСЛЕДОВАТЕЛЬНОСТИ ИММУНОГЛОБУЛИНОВ
DK2825036T3 (en) 2012-03-16 2018-07-16 Regeneron Pharma Histidine engineered light chain antibodies and genetically modified rodents to generate them
HUE042117T2 (hu) * 2012-08-21 2019-06-28 Sanofi Biotechnology Eljárások asztma kezelésére vagy megelõzésére IL-4R antagonista beadásával
AR092177A1 (es) 2012-08-21 2015-03-25 Sanofi Sa Metodos para tratar o prevenir asma administrando un antagonista de il-4r
CN118286417A (zh) * 2012-09-07 2024-07-05 瑞泽恩制药公司 以il-4r拮抗剂治疗特应性皮炎的方法
KR102284244B1 (ko) * 2012-09-07 2021-08-03 리제너론 파아마슈티컬스, 인크. Ｉｌ-4ｒ 길항제 투여로 아토피성 피부염을 치료하는 방법
AR095196A1 (es) 2013-03-15 2015-09-30 Regeneron Pharma Medio de cultivo celular libre de suero
US10111953B2 (en) 2013-05-30 2018-10-30 Regeneron Pharmaceuticals, Inc. Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
TWI633891B (zh) * 2013-06-04 2018-09-01 再生元醫藥公司 藉由投與ｉｌ－４ｒ抑制劑以治療過敏及增強過敏原－特異之免疫療法的方法
ES2747630T3 (es) * 2013-06-21 2020-03-11 Sanofi Biotechnology Métodos de tratamiento de poliposis nasal administrando un antagonista de IL-4R
SI3010539T1 (sl) 2013-06-21 2019-11-29 Regeneron Pharma Postopki za zdravljenje nazalne polipoze z administriranjem antagonista IL-4R
TWI634900B (zh) 2013-07-11 2018-09-11 再生元醫藥公司 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法
EP3068803B1 (en) 2013-11-12 2021-01-20 Sanofi Biotechnology Dosing regimens for use with pcsk9 inhibitors
DE112014005975T5 (de) * 2013-12-17 2016-09-15 Kymab Limited Menschliche Ziele
US8980273B1 (en) 2014-07-15 2015-03-17 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US8986691B1 (en) 2014-07-15 2015-03-24 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
WO2015107126A1 (en) * 2014-01-16 2015-07-23 Mondelli Mario Umberto Francesco Neutralizing human monoclonal antibodies against hepatitis b virus surface antigen
EP3973987B1 (en) * 2014-02-21 2024-01-10 Sanofi Biotechnology Combination comprising an il-4r antagonist, a corticosteroid and a long-acting beta2-adrenergic agonist for treating asthma
IL247290B (en) * 2014-02-21 2021-06-30 Sanofi Biotechnology Methods of treating or preventing asthma by adding an il-4r antagonist
AU2015222951B2 (en) * 2014-02-28 2020-06-11 Regeneron Pharmaceuticals, Inc. Methods for treating skin infection by administering an IL-4R antagonist
AU2015230938C1 (en) 2014-03-21 2021-10-14 Regeneron Pharmaceuticals, Inc. Non-human animals that make single domain binding proteins
KR20240017117A (ko) 2014-07-16 2024-02-06 사노피 바이오테크놀로지 이형접합성 가족성 고콜레스테롤혈증(heFH) 환자의 치료방법
IL303337A (en) 2014-11-14 2023-08-01 Regeneron Pharma Methods for the treatment of chronic sinusitis with nasal polyps by adding an R4–IL antagonist
WO2016149678A1 (en) 2015-03-19 2016-09-22 Regeneron Pharmaceuticals, Inc. Non-human animals that select for light chain variable regions that bind antigen
CA3232651A1 (en) 2015-04-02 2016-10-06 Intervet International B.V. Antibodies to canine interleukin-4 receptor alpha
TWI797060B (zh) 2015-08-04 2023-04-01 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法
CA2995645A1 (en) 2015-08-18 2017-02-23 Regeneron Pharmaceuticals, Inc. Anti-pcsk9 inhibitory antibodies for treating patients with hyperlipidemia undergoing lipoprotein apheresis
CA3014202A1 (en) 2016-02-19 2017-08-24 Regeneron Pharmaceuticals, Inc. Methods for enhancing efficacy of a vaccine by administering an il-4r antagonist
CN113372446A (zh) * 2016-06-08 2021-09-10 苏州康乃德生物医药有限公司 用于结合白细胞介素4受体的抗体
WO2018039499A1 (en) 2016-08-24 2018-03-01 Regeneron Pharmaceuticals, Inc. Host cell protein modification
KR20240065318A (ko) 2016-09-01 2024-05-14 리제너론 파아마슈티컬스, 인크. Il-4r 길항제를 투여함에 의해 알레르기를 예방하거나 치료하기 위한 방법
US10485844B2 (en) 2016-09-22 2019-11-26 Regeneron Pharmaceuticals, Inc. Methods for treating severe atopic dermatitis by administering an IL-4R inhibitor
MX2019003235A (es) 2016-09-22 2019-07-08 Regeneron Pharma Metodos para tratar dermatitis atopica severa administrando un inhibidor de receptor de isoleucina-4.
KR20190091290A (ko) 2016-11-29 2019-08-05 리제너론 파아마슈티컬스, 인크. Ｐｒｌｒ 양성 유방암 치료 방법
TW202332696A (zh) * 2016-12-01 2023-08-16 美商再生元醫藥公司 治療發炎症狀的方法
MX2019012171A (es) 2017-04-13 2019-11-25 Regeneron Pharma Tratamiento e inhibicion de enfermedades pulmonares inflamatorias en pacientes que tienen alelos de riesgo en los genes que codifican la il33 e il1rl1.
KR20210084695A (ko) 2017-07-06 2021-07-07 리제너론 파마슈티칼스 인코포레이티드 당단백질을 만들기 위한 세포 배양 과정
US11053309B2 (en) 2017-08-04 2021-07-06 Regeneron Pharmaceuticals, Inc. Methods for treating active eosinophilic esophagitis
MX2020004467A (es) 2017-10-30 2020-10-22 Sanofi Biotechnology Metodos para el tratamiento o la prevencion del asma mediante la administracion de antagonista de il-4r.
WO2019126123A1 (en) 2017-12-22 2019-06-27 Regeneron Pharmaceuticals, Inc. System and method for characterizing drug product impurities
MX2020008095A (es) 2018-01-31 2020-09-24 Regeneron Pharma Sistemas y métodos para caracterizar variantes de tamaño y carga de impurezas de productos farmacológicos.
CN110105451B (zh) * 2018-02-01 2020-12-18 北京凯因科技股份有限公司 IL-4Rα抗体及其用途
WO2019148405A1 (zh) * 2018-02-01 2019-08-08 北京凯因科技股份有限公司 IL-4Rα抗体及其用途
TWI786265B (zh) 2018-02-02 2022-12-11 美商再生元醫藥公司 用於表徵蛋白質二聚合之系統及方法
JP2021514609A (ja) 2018-02-28 2021-06-17 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ウイルス混入物質を同定するためのシステムおよび方法
KR102503356B1 (ko) 2018-03-19 2023-02-24 리제너론 파마슈티칼스 인코포레이티드 마이크로칩 모세관 전기영동 분석 및 시약
SG11202008707YA (en) * 2018-03-22 2020-10-29 Surface Oncology Inc Anti-il-27 antibodies and uses thereof
CN108373505B (zh) * 2018-04-20 2019-08-20 北京智仁美博生物科技有限公司 抗il-4r抗体及其用途
TW202016125A (zh) 2018-05-10 2020-05-01 美商再生元醫藥公司 用於定量及調節蛋白質黏度之系統與方法
MX2020012064A (es) 2018-05-13 2021-04-13 Regeneron Pharma Metodos para tratar la dermatitis atopica administrando un inhibidor de il-4r.
CN113101364B (zh) * 2018-05-29 2023-12-01 康诺亚生物医药科技（成都）有限公司 一种自免疫抑制剂的开发和应用
KR20210030378A (ko) * 2018-07-10 2021-03-17 리제너론 파마슈티칼스 인코포레이티드 기존 상호작용을 최소화하는 결합 분자의 변형
BR112021002989A2 (pt) 2018-08-24 2021-05-11 Jiangsu Hengrui Medicine Co., Ltd. anticorpo para ligação de il-4r de humano, fragmento para ligação de antígeno e uso médico do mesmo
CA3100035A1 (en) 2018-08-27 2020-03-05 Regeneron Pharmaceuticals, Inc. Use of raman spectroscopy in downstream purification
US11754569B2 (en) 2018-08-30 2023-09-12 Regeneron Pharmaceuticals, Inc. Methods for characterizing protein complexes
CN110872349A (zh) * 2018-09-04 2020-03-10 三生国健药业（上海）股份有限公司 结合人il-4r的抗体、其制备方法和用途
CN113166259A (zh) * 2018-11-09 2021-07-23 亚洲大学校产学协力团 对人IL-4受体α具有高亲和力的人抗体及其用途
US11312778B2 (en) 2018-11-21 2022-04-26 Brian C. Machler Method for treating allergic contact dermatitis
CN111518211B (zh) * 2018-12-25 2022-06-21 江苏荃信生物医药股份有限公司 抗人白介素4受体α单克隆抗体的制药用途
KR20210114927A (ko) 2019-01-16 2021-09-24 리제너론 파마슈티칼스 인코포레이티드 이황화 결합을 특징 짓는 방법
MX2021010560A (es) 2019-03-06 2021-11-12 Regeneron Pharma Inhibidores de la via il-4/il-13 para una eficacia aumentada en el tratamiento de cancer.
CN113597328A (zh) 2019-03-21 2021-11-02 瑞泽恩制药公司 用于治疗过敏症的il-4/il-13途径抑制剂和浆细胞消融的组合
CA3135004A1 (en) 2019-05-13 2020-11-19 Regeneron Pharmaceuticals, Inc. Improved competitive ligand binding assays
CN112010977B (zh) * 2019-05-29 2022-04-26 山东博安生物技术股份有限公司 抗白介素4受体(il-4r)的抗体及其应用
CN110343666B (zh) * 2019-07-10 2023-05-30 通化东宝药业股份有限公司 一种cho细胞培养的补料培养基及其制备方法和应用
SG11202113310UA (en) 2019-08-05 2021-12-30 Regeneron Pharma Methods for treating atopic dermatitis by administering an il-4r antagonist
AU2020325021B2 (en) 2019-08-05 2024-05-30 Regeneron Pharmaceuticals, Inc. Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an IL-4R antagonist
BR112022004885A2 (pt) 2019-09-24 2022-06-07 Regeneron Pharma Sistemas e métodos para uso e regeneração de cromatografia
CN111825766B (zh) * 2019-10-31 2021-05-11 上海洛启生物医药技术有限公司 抗il-4r单域抗体及其应用
CA3158119A1 (en) 2019-11-25 2021-06-03 Regeneron Pharmaceuticals, Inc. Sustained release formulations using non-aqueous emulsions
EP3992974A1 (en) 2020-11-02 2022-05-04 Sanofi Biotechnology Methods for treating digitally-identified il-4/il-13 related disorders
CA3161037A1 (en) 2019-12-09 2021-06-17 Sanofi Biotechnology Methods for treating digitally-identified il-4/il-13 related disorders
BR122023021668A2 (pt) 2020-01-21 2024-01-09 Regeneron Pharmaceuticals, Inc. Método para determinar a estabilidade de uma proteína de interesse
TW202139974A (zh) 2020-02-21 2021-11-01 大陸商江蘇恆瑞醫藥股份有限公司 一種抗ｉｌ－４ｒ抗體醫藥組成物及其用途
BR112022017174A2 (pt) * 2020-02-27 2022-10-18 Chia Tai Tianqing Pharmaceutical Group Co Ltd Anticorpo monoclonal isolado, ou uma porção de ligação ao antígeno do mesmo, nucleotídeo, vetor de expressão, célula hospedeira, composição farmacêutica e métodos de tratamento de uma doença alérgica e de um tumor
EP4126951A1 (en) 2020-03-27 2023-02-08 Regeneron Pharmaceuticals, Inc. Methods for treating atopic dermatitis by administering an il-4r antagonist
CA3174431A1 (en) 2020-05-22 2021-11-25 Jennifer D. Hamilton Methods for treating eosinophilic esophagitis by administering an il-4r inhibitor
WO2022047108A1 (en) 2020-08-31 2022-03-03 Regeneron Pharmaceuticals, Inc. Asparagine feed strategies to improve cell culture performance and mitigate asparagine sequence variants
CA3194111A1 (en) 2020-10-05 2022-04-14 Christine XU Methods for treating asthma in pediatric subjects by administering an il-4r antagonist
CN116940347A (zh) 2020-11-25 2023-10-24 里珍纳龙药品有限公司 使用非水性膜乳化的持续释放调配物
JP2024500409A (ja) 2020-12-17 2024-01-09 リジェネロン・ファーマシューティカルズ・インコーポレイテッド タンパク質封入マイクロゲルの作製
JP2023554557A (ja) * 2020-12-22 2023-12-27 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司 抗ｉｌ－４ｒ抗体又はその抗原結合断片の複合物及び医薬用途
CA3204515A1 (en) 2021-01-08 2022-07-14 Jamie M. Orengo Methods for treating peanut allergy and enhancing peanut allergen-specific immunotherapy by administering an il-4r antagonist
MX2023008527A (es) 2021-01-20 2023-07-28 Regeneron Pharma Metodos para mejorar el valor proteico en cultivo celular.
US20220404369A1 (en) 2021-03-03 2022-12-22 Regeneron Pharmaceuticals, Inc. Systems and methods for quantifying and modifying protein viscosity
AU2022243005A1 (en) 2021-03-26 2023-10-05 Regeneron Pharmaceuticals, Inc. Methods and systems for developing mixing protocols
EP4348234A1 (en) 2021-06-01 2024-04-10 Regeneron Pharmaceuticals, Inc. Micropchip capillary electrophoresis assays and reagents
MX2024001189A (es) 2021-07-26 2024-02-27 Sanofi Biotechnology Metodos para tratar la urticaria cronica espontanea por administracion de un antagonista de il-4r.
CA3228708A1 (en) 2021-08-10 2023-02-16 Kymab Limited Treatment of atopic dermatitis
AU2022333073A1 (en) 2021-08-23 2024-04-04 Regeneron Pharmaceuticals, Inc. Methods for treating atopic dermatitis by administering an il-4r antagonist
WO2023025217A1 (zh) * 2021-08-26 2023-03-02 正大天晴药业集团股份有限公司 抗il4r抗体的药物组合物及其用途
TW202326138A (zh) 2021-09-08 2023-07-01 美商再生元醫藥公司 用於定量抗體及其他含Ｆｃ蛋白之高通量及基於質譜之方法
CN118139881A (zh) 2021-09-20 2024-06-04 瑞泽恩制药公司 控制抗体异质性的方法
MX2024003921A (es) 2021-09-30 2024-04-22 Regeneron Pharma Variantes de la reticulocalbina-3 (rcn3) y tratamiento del asma con antagonistas del receptor alfa de la interleucina-4 (il4r).
EP4413359A1 (en) 2021-10-07 2024-08-14 Regeneron Pharmaceuticals, Inc. Ph meter calibration and correction
IL311245A (en) 2021-10-07 2024-05-01 Regeneron Pharma Systems and methods for pH modeling and control
US20230183362A1 (en) 2021-10-20 2023-06-15 Sanofi Biotechnology Methods for treating prurigo nodularis by administering an il-4r antagonist
AU2022376179A1 (en) 2021-10-26 2024-05-16 Regeneron Pharmaceuticals, Inc. Systems and methods for generating laboratory water and distributing laboratory water at different temperatures
WO2023085978A1 (en) * 2021-11-11 2023-05-19 Joint Stock Company «Biocad» Monoclonal antibody or antigen-binding fragment thereof that specifically binds to il-4ra, and use thereof
WO2023086887A1 (en) 2021-11-11 2023-05-19 Regeneron Pharmaceuticals, Inc. Treatment of lung disease based upon stratification of polygenic risk score for interleukin 33 (il-33)
IL312714A (en) * 2021-11-18 2024-07-01 Twist Bioscience Corp DICKKOPF-1 variant antibodies and methods of use
WO2023102383A1 (en) 2021-11-30 2023-06-08 Regeneron Pharmaceuticals, Inc. Treatment of lung disease based upon stratification of polygenic score relating to response to a therapeutic agent
AU2022425608A1 (en) 2021-12-30 2024-08-15 Regeneron Pharmaceuticals, Inc. Methods for attenuating atopic march by administering an il-4/il-13 antagonist
TW202340252A (zh) 2022-01-29 2023-10-16 大陸商上海盛迪醫藥有限公司 糖皮質激素的藥物偶聯物
WO2023167850A1 (en) 2022-03-02 2023-09-07 Regeneron Pharmaceuticals, Inc. Manufacturing process for high titer antibody
US20230296559A1 (en) 2022-03-18 2023-09-21 Regeneron Pharmaceuticals, Inc. Methods and systems for analyzing polypeptide variants
WO2023191665A1 (en) * 2022-03-31 2023-10-05 Milaboratory, Limited Liability Company ANTIBODIES TO HUMAN IL-4Rα HAVING REDUCED IMMUNOGENICITY AND APPLICATION THEREOF
WO2024011251A1 (en) 2022-07-08 2024-01-11 Regeneron Pharmaceuticals, Inc. Methods for treating eosinophilic esophagitis in pediatric by administering an il-4r antagonist
WO2024047021A1 (en) 2022-08-29 2024-03-07 Sanofi Methods for treating chronic inducible cold urticaria by administering an il-4r antagonist
KR20240038841A (ko) 2022-09-16 2024-03-26 연세대학교 산학협력단 신규한 인간 인터류킨-4 수용체 결합 나노바디 및 이의 용도
US20240141051A1 (en) 2022-11-01 2024-05-02 Regeneron Pharmaceuticals, Inc. Methods for treating hand and foot dermatitis by administering an il-4r antagonist
WO2024112935A1 (en) 2022-11-23 2024-05-30 Regeneron Pharmaceuticals, Inc. Methods for improving bone growth by administering an il-4r antagonist
WO2024130048A1 (en) 2022-12-16 2024-06-20 Regeneron Pharmaceuticals, Inc. Methods and systems for assessing chromatographic column integrity
US20240245779A1 (en) 2023-01-25 2024-07-25 Regeneron Pharmaceuticals, Inc. Methods of modeling liquid protein composition stability
WO2024158961A1 (en) 2023-01-25 2024-08-02 Regeneron Pharmaceuticals, Inc. Mass spectrometry-based characterization of antibodies co-expressed in vivo
WO2024163708A1 (en) 2023-02-01 2024-08-08 Regeneron Pharmaceuticals, Inc. Asymmetrical flow field-flow fractionation with mass spectrometry for biomacromolecule analysis

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5041381A (en) * 1986-07-03 1991-08-20 Schering Corporation Monoclonal antibodies against human interleukin-4 and hybridomas producing the same
GB8808015D0 (en) * 1988-04-06 1988-05-05 Ritter M A Chemical compounds
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
WO1990005183A1 (en) * 1988-10-31 1990-05-17 Immunex Corporation Interleukin-4 receptors
WO1992019259A1 (en) * 1991-05-03 1992-11-12 Seragen, Inc. Interleukin receptor targeted molecules for treatment of inflammatory arthritis
DE69321218T2 (de) * 1992-02-19 1999-02-18 Schering Corp., Kenilworth, N.J. Klonierung und expression von humanisierten monoklonalen antikörpern gegen menschliches interleukin-4
AU675661B2 (en) 1992-07-24 1997-02-13 Abgenix, Inc. Generation of xenogeneic antibodies
US5714146A (en) * 1992-08-26 1998-02-03 Board Of Regents Of The University Of Washington IL-4 bone therapy
EP0604693A1 (en) * 1992-12-29 1994-07-06 Schering-Plough Monoclonal antibodies against the human interleukin-4 receptor and hybridomas producing the same
RU2162711C2 (ru) * 1993-09-07 2001-02-10 Смитклайн Бичам Корпорейшн Рекомбинантные il4-антитела, используемые для лечения нарушений, связанных с действием il4
US6387632B2 (en) * 1998-06-11 2002-05-14 Hitachi, Ltd. Polynucleotide separation method and apparatus therefor
US6787637B1 (en) 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
EP1283851B1 (en) 2000-05-26 2012-03-28 Immunex Corporation Use of il-4r antibodies and compositions thereof
US7879328B2 (en) * 2000-06-16 2011-02-01 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
ATE548388T1 (de) 2003-11-07 2012-03-15 Immunex Corp An den interleukin-4-rezeptor bindende antikörper
US7884054B2 (en) * 2003-12-22 2011-02-08 Amgen Inc. Methods for identifying functional antibodies
JP2008504806A (ja) 2004-02-27 2008-02-21 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｉｌ−４／ｉｌ−１３特異的ポリペプチドおよびその治療上の使用
US20090098142A1 (en) * 2004-06-09 2009-04-16 Kasaian Marion T Methods and compositions for treating and monitoring treatment of IL-13-associated disorders
AR049390A1 (es) * 2004-06-09 2006-07-26 Wyeth Corp Anticuerpos contra la interleuquina-13 humana y usos de los mismos
PE20060560A1 (es) * 2004-08-03 2006-06-27 Novartis Ag Anticuerpos de interleucina-4 humana
TW200902555A (en) 2005-01-03 2009-01-16 Hoffmann La Roche Antibodies against IL-13 receptor alpha 1 and uses thereof
DK2041177T3 (da) 2006-06-02 2012-02-27 Regeneron Pharma Højaffinitetsantistoffer mod human IL-6-receptor
US7608693B2 (en) * 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
DK2069403T3 (da) 2006-10-02 2014-07-28 Regeneron Pharma Human-antistoffer med høj affinitet for human IL-4 receptor
EP3354280B1 (en) * 2010-10-06 2020-07-29 Regeneron Pharmaceuticals, Inc. Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies
AR092177A1 (es) * 2012-08-21 2015-03-25 Sanofi Sa Metodos para tratar o prevenir asma administrando un antagonista de il-4r
TWI633891B (zh) * 2013-06-04 2018-09-01 再生元醫藥公司 藉由投與ｉｌ－４ｒ抑制劑以治療過敏及增強過敏原－特異之免疫療法的方法
SI3010539T1 (sl) * 2013-06-21 2019-11-29 Regeneron Pharma Postopki za zdravljenje nazalne polipoze z administriranjem antagonista IL-4R
EP3973987B1 (en) * 2014-02-21 2024-01-10 Sanofi Biotechnology Combination comprising an il-4r antagonist, a corticosteroid and a long-acting beta2-adrenergic agonist for treating asthma
IL303337A (en) * 2014-11-14 2023-08-01 Regeneron Pharma Methods for the treatment of chronic sinusitis with nasal polyps by adding an R4–IL antagonist

Also Published As

Publication number Publication date
JP6449125B2 (ja) 2019-01-09
MY152448A (en) 2014-09-30
FR18C1011I2 (fr) 2020-03-06
SMT201300074B (it) 2013-09-06
EP3064511B1 (en) 2018-04-18
HRP20181148T1 (hr) 2018-09-21
NO2023019I1 (no) 2023-05-02
NO2018009I2 (no) 2019-01-30
CN103739711B (zh) 2016-09-14
HK1250733A1 (zh) 2019-01-11
CN102197052A (zh) 2011-09-21
NI201100064A (es) 2011-11-02
PT3064511T (pt) 2018-07-17
ZA201101867B (en) 2012-08-29
SI3064511T1 (en) 2018-08-31
JP6843208B2 (ja) 2021-03-17
UY32213A (es) 2010-05-31
EP3715372A1 (en) 2020-09-30
US20130078675A1 (en) 2013-03-28
RU2014147773A (ru) 2016-06-20
JP2019055963A (ja) 2019-04-11
JP2024040526A (ja) 2024-03-25
PH12014500462A1 (en) 2015-06-01
TWI658833B (zh) 2019-05-11
RU2539774C2 (ru) 2015-01-27
RS65385B1 (sr) 2024-04-30
LT3715372T (lt) 2024-03-25
RS52782B (en) 2013-10-31
EP4345111A2 (en) 2024-04-03
US20120052072A1 (en) 2012-03-01
HUS1800014I1 (hu) 2018-03-28
US20210163611A1 (en) 2021-06-03
DK3715372T5 (da) 2024-08-26
EP2356151B1 (en) 2013-04-10
PT3351560T (pt) 2020-05-11
JP2016041069A (ja) 2016-03-31
AU2009311496A1 (en) 2010-05-14
CR20110148A (es) 2011-04-27
HRP20130467T1 (en) 2013-06-30
CY1114123T1 (el) 2016-07-27
PT2356151E (pt) 2013-05-07
PT3715372T (pt) 2024-03-14
WO2010053751A1 (en) 2010-05-14
SI3715372T1 (sl) 2024-05-31
TWI538686B (zh) 2016-06-21
IL211726A (en) 2015-10-29
TW201919700A (zh) 2019-06-01
JO2865B1 (en) 2015-03-15
SV2011003880A (es) 2011-08-15
NL300922I2 (nl) 2019-01-15
JP2022160404A (ja) 2022-10-19
BRPI0919853B1 (pt) 2020-10-27
DK3715372T3 (da) 2024-03-11
ES2404206T3 (es) 2013-05-24
NZ591922A (en) 2012-03-30
US20180179288A1 (en) 2018-06-28
IL211726A0 (en) 2011-06-30
EP3064511A1 (en) 2016-09-07
LUC00059I1 (el) 2018-01-03
KR20110074980A (ko) 2011-07-05
FR18C1011I1 (el) 2018-04-27
ES2975006T3 (es) 2024-07-02
EP3351560B1 (en) 2020-04-22
CY2018003I1 (el) 2018-09-05
CN106267190B (zh) 2021-01-26
EP2636685A1 (en) 2013-09-11
CN106267190A (zh) 2017-01-04
US20090074793A1 (en) 2009-03-19
AU2009311496B9 (en) 2014-10-30
AR073978A1 (es) 2010-12-15
CL2009002004A1 (es) 2010-03-05
CN103739711A (zh) 2014-04-23
RU2539774C3 (ru) 2020-11-06
MX2011003346A (es) 2011-04-21
CO6362024A2 (es) 2012-01-20
EP4345111A3 (en) 2024-05-22
BRPI0919853B8 (pt) 2021-05-25
US8735095B2 (en) 2014-05-27
ECSP11011010A (es) 2011-06-30
NZ596093A (en) 2012-11-30
EP3351560A1 (en) 2018-07-25
CN102197052B (zh) 2014-02-12
EP2511300A3 (en) 2012-11-07
US8337839B2 (en) 2012-12-25
MA32802B1 (fr) 2011-11-01
JP7100731B2 (ja) 2022-07-13
JP5291802B2 (ja) 2013-09-18
KR101599706B1 (ko) 2016-03-04
DK3064511T3 (en) 2018-07-16
DK2356151T3 (da) 2013-06-17
LTC2356151I2 (lt) 2019-04-10
US7608693B2 (en) 2009-10-27
RS57522B1 (sr) 2018-10-31
US20100047254A1 (en) 2010-02-25
PL3715372T3 (pl) 2024-06-24
CY1122092T1 (el) 2020-07-31
JP2013223495A (ja) 2013-10-31
EP2356151A1 (en) 2011-08-17
CA2737044A1 (en) 2010-05-14
LTPA2018002I1 (lt) 2018-02-12
EP2511300A2 (en) 2012-10-17
MX356882B (es) 2018-06-19
PL2356151T3 (pl) 2013-08-30
AU2009311496B2 (en) 2014-05-29
JP2021087440A (ja) 2021-06-10
ES2675917T3 (es) 2018-07-13
CA2737044C (en) 2017-02-28
JP7442581B2 (ja) 2024-03-04
HRP20240492T1 (hr) 2024-07-05
PE20100738A1 (es) 2010-11-03
UA102122C2 (ru) 2013-06-10
CY2018003I2 (el) 2018-09-05
BRPI0919853A2 (pt) 2016-03-15
NO2018009I1 (no) 2018-03-06
RU2011120194A (ru) 2012-12-10
LT3064511T (lt) 2018-07-10
RU2663106C2 (ru) 2018-08-01
JP5844772B2 (ja) 2016-01-20
TW201029664A (en) 2010-08-16
JP6608505B2 (ja) 2019-11-20
LUC00059I2 (el) 2018-03-28
TW201615216A (zh) 2016-05-01
PL3351560T3 (pl) 2020-09-21
US20140271681A1 (en) 2014-09-18
HUE039212T2 (hu) 2018-12-28
JP2020007378A (ja) 2020-01-16
SI2356151T1 (sl) 2013-07-31
EP3715372B1 (en) 2024-01-24
HN2011001210A (es) 2013-10-22
US8075887B2 (en) 2011-12-13
JP2012507294A (ja) 2012-03-29
ES2802241T3 (es) 2021-01-18
PA8847001A1 (es) 2010-05-26
FI3715372T3 (fi) 2024-03-18
PL3064511T3 (pl) 2018-09-28

Similar Documents

Publication Publication Date Title
HRP20130467T1 (en) High affinity human antibodies to human il-4 receptor
HK1200846A1 (en) High affinity human antibodies to human il-4 receptor il-4
HUS1700029I1 (hu) Nagy affinitású PCSK9 elleni humán testek
HK1205470A1 (en) High affinity human antibodies to human angiopoietin-2 -2